Gilead Sciences (NASDAQ:GILD)

Short Sellers Raise the Stakes in Major Biotechs

The short interest data are out for the most recent settlement date, May 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Why Big Pharma Is Not at Fault for Record Drug Spending

With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag. But the truth is, Big ...
Read Full Story »

Major Biotech Short Interest Remains Mixed

The short interest data are out for the most recent settlement date, April 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Gilead Faces Serious Conundrum: Value Trap vs Real Value

Gilead Sciences Inc. (NASDAQ: GILD) had perhaps become the greatest biotech growth story of all time. In a world that only rewards what you will do next rather than what ...
Read Full Story »

Value or Value Trap: Meet the 21 S&P 500 Stocks Valued Under 10 Times Earnings

The bull market is now well over eight years old, and investors are looking for new ideas for how they should be investing their money. Stocks, bonds and commodities are all ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, April 13. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Analysts See 10 Companies Beating Expectations This Earnings Season

With earnings starting to really snowball next week, and a market that seems to be teetering somewhat due to high valuations and some messy geopolitical issues, it makes sense for ...
Read Full Story »

Short Sellers Back Off Major Biotechs

The short interest data are out for the most recent settlement date, March 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

If any industry has been under pressure over the past year or so, it has been biotechnology. While there are some positives for the industry, it still faces some definite ...
Read Full Story »

Short Interest Pulls Back in Major Biotechs

The short interest data are out for the most recent settlement date, March 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

How Health Care Stocks Responded to the Shelved Health Care Bill

Despite touting himself as an incredible dealmaker and negotiater, Trump faced the biggest defeat of his presidency thus far when legislation to repeal the Affordable Care Act was pulled from ...
Read Full Story »

Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now

If any sector is offering value in what really appears to be a very overbought stock market, it is pharmaceutical, including biotechnology. Absolutely battered during the election cycle when rhetoric over ...
Read Full Story »

What a Combined Gilead and Incyte Would Look Like

Gilead Sciences Inc. (NASDAQ: GILD) has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AIG, Boeing, GameStop, Gilead, Starbucks, CIGNA, Ciena, Ferrari and Many More

Stocks were indicated to open marginally higher on Monday, but all eyes remain on the Federal Open Market Committee (FOMC) ahead of this week's interest rate hike decision. The odds ...
Read Full Story »

Major Biotechs See a Retreat in Short Interest

The short interest data are out for the most recent settlement date, February 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »